| Authors | Arms | Mean age | Duration (wk) | Sample size | Baseline MADRS score | Study location | Entry score by MADRS | Year of publication | References |
| Baldwin |
|
| 8 |
|
| Europe-Asia | ≥26 | 2012 | [22] |
|
| Placebo | 43.4 |
| 145 | 29.8 ± 5.1 |
|
|
|
|
|
| VTX 2.5 mg | 46 |
| 155 | 29.6 ± 5.8 |
|
|
|
|
|
| VTX 5 mg | 44.7 |
| 155 | 31.3 ± 5.8 |
|
|
|
|
|
| VTX 10 mg | 45.2 |
| 151 | 30.4 ± 5.4 |
|
|
|
|
|
| DLX 60 mg | 45.3 |
| 149 | 29.9 ± 5.8 |
|
|
|
|
| Katona |
|
| 8 |
|
| Usa- Europe-Asia | ≥26 | 2012 | [23] |
|
| Placebo | 70.3 |
| 145 | 29.4 ± 5.1 |
|
|
|
|
|
| VTX 5 mg | 70.5 |
| 156 | 29.2 ± 5 |
|
|
|
|
|
| DLX 60 mg | 70.9 |
| 151 | 28.5 ± 4.9 | Usa | ≥26 | 2013 |
|
| Mahablashwarkar |
|
| 8 |
|
|
|
|
| [24] |
|
| Placebo | 42.6 |
| 153 | 29.5 ± 6.1 |
|
|
|
|
|
| VTX 2.5 mg | 42.6 |
| 153 | 29.8 ± 5.4 |
|
|
|
|
|
| VTX 5 mg | 43.1 |
| 153 | 29.8 ± 4.5 |
|
|
|
|
|
| DLX 60 mg | 42.7 |
| 152 | 29.4 ± 4.4 |
|
|
|
|
| Boulenger |
|
| 8 |
|
| Europe | ≥26 | 2013 | [25] |
|
| Placebo | 48.1 |
| 158 | 31.5 ± 3.6 |
|
|
|
|
|
| VTX 15 mg | 47 |
| 151 | 31.8 ± 3.4 |
|
|
|
|
|
| VTX 20 mg | 46.2 |
| 151 | 31.2 ± 3.4 |
|
|
|
|
|
| DLX 60 mg | 45.6 |
| 147 | 31.2 ± 3.5 |
|
|
|
|
| Mahablashwarkar |
|
| 8 |
|
| Usa | ≥26 | 2014 | [26] |
|
| Placebo | 42.4 |
| 161 | 31.6 ± 4.18 |
|
|
|
|
|
| VTX 15 mg | 43.1 |
| 147 | 31.9 ± 4.08 |
|
|
|
|
|
| VTX 20 mg | 42.8 |
| 154 | 32 ± 4.36 |
|
|
|
|
|
| DLX 60 mg | 43.4 |
| 152 | 32.9 ± 4.39 |
|
|
|
|